Health & Medical, UK (Commonwealth Union) – Motor Neuron Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS), is a progressive neurological disorder that affects the nerve cells responsible for controlling voluntary muscles. This debilitating condition gradually leads to muscle weakness, paralysis, and, in some cases, respiratory failure. In this article, we will delve into the causes, symptoms, and treatment options for Motor Neuron Disease.
Motor Neuron Disease primarily affects the motor neurons, which control voluntary muscle movement. The onset and progression of symptoms can vary between individuals, but common signs and symptoms include Muscle Weakness, Muscle Atrophy, Spasticity, Difficulty in Speech and Swallowing as well as Respiratory Issues.
The American Food and Drug Administration (FDA) recently authorized the 1st approved drug for a rare form of MND that was linked to the results of a Phase 3 clinical trial done at the University of Sheffield, the UK center of a global trial.
Findings from the Phase 3 clinical trial, led in the UK by Professor Dame Pamela Shaw, Director of the Neuroscience Institute and the Sheffield Institute for Translational Neuroscience (SITraN) as well as Professor Chris McDermott, who is Professor of Translational Neurology at the University of Sheffield, demonstrated that patients having the faulty SOD1 gene regularly observe the progression at a lesser pace of their symptoms and in certain instances improvement of muscle strength following the administration of the investigational drug QALSODY™, referred to as Tofersen on prior occasions.
Biogen Inc. a biotech company is responsible for taking the new drug to the American market and scientists expect application submissions seeking approval in the UK and EU in the near future.
Researchers described this is a key scientific advance being the 1st treatment taking aim at a genetic cause of MND and will alter the way researchers carry out clinical trials in MND in the coming years ahead.
The trial consisted of 108 MND patients recognized for the faulty SOD1 gene. In spite no vital clinical enhancement being observed at the primary endpoint of the research at 28 weeks, when the observing period was stretched to 52 weeks, notable clinical enhancements were noted in terms of muscle strength, breathing function as well as disability levels.
Professor Dame Pamela Shaw from the University of Sheffield, indicated that she has carried out over 25 MND clinical trials and this was the 1st trial where patients have showed an enhancement in their muscle strength.
“Never before have I heard patients say ‘I am doing things today that I couldn’t do a few months ago – walking up the garden steps or writing Christmas cards’. For me this is an important treatment milestone.”
She further indicated that the trial helped them learn that they can observer changes in biochemistry within 2-3 months however they have to be a bit more patient to notice any key clinical changes.
“Although not yet approved for use in the UK and Europe, FDA approval is a major scientific development . While awaiting the regulatory permissions to prescribe QALSODY™, Biogen are making the treatment available for patients with a confirmed SOD1 mutation through an expanded access programme.”
The findings from the Phase 3 clinical trial (VALOR), that appeared in the New England Journal of Medicine, had demonstrated that biomarkers in patients’ cerebrospinal fluid displayed a lowering in the SOD1 and neurofilament protein levels following the use of QALSODY for 6 months. This had pointed out that the treatment successfully reaches the therapeutic target and lowers the loss of motor neurones, which may permit them to begin regenerating connections with muscles in the body. But it took more time for patients to experience better muscle strength, according to researchers.
